Why Breakthroughs Are Slowing—and How to Fix It

Innovation is the lifeblood of modern economies and a key to solving society’s most urgent challenges. But despite headlines celebrating AI, biotech, and space tourism, the broader global innovation ecosystem is showing signs of fatigue. Across industries and nations, four structural forces are choking off the long-term creativity on which progress depends: declining internal R&D, the rise of financial short-termism, monopolistic patent regimes, and increasing market concentration.

These barriers are not simply bureaucratic quirks. They are reshaping capitalism at a fundamental level—directing capital away from labs and into stock buybacks, shielding old technologies from disruption, and locking out the very entrepreneurs who might deliver the next big leap forward.

Where Has All the Research Gone?

The decline in internal corporate R&D (Damodaran, stern.nyu.edu) is perhaps the most telling symptom of innovation malaise. Gone are the days when firms like Bell Labs or Xerox PARC pioneered world-changing technologies in-house. Today, large firms often outsource their innovation to startups or acquire it wholesale. In pharmaceuticals, this is the norm: big firms now spend billions buying biotech companies rather than discovering drugs in-house. It is a strategy dubbed “Search & Development.”

But what happens when everyone is searching and no one is developing?

In the traditional energy sector, R&D is almost nonexistent. Oil and gas companies reinvest less than 1% of their revenues into R&D . In contrast, pharmaceutical companies average 25–30%, reflecting the higher risk—and higher potential—of medical breakthroughs (stern.nyu.edu). Nevertheless, the pharmaceutical industry has seen a shift from large, vertically integrated companies carrying out virtually all stages of drug discovery to large companies with less innovation, and an increase in vertical disintegration and horizontal integration through mergers and acquisitions; financialization in the pharmaceutical industry suggests the strategic priority has shifted from delivering value to customers to delivering value to shareholders (Susan Sell, Australian National University).

Wall Street’s Grip on Innovation

In 2018, S&P 500 companies spent a staggering $806 billion on stock buybacks—more than all U.S. firms spent on research and development combined ($608 billion) (S&P Global). The short-term incentives of financial markets now consistently overpower long-term innovation.

Nowhere is this more alarming than in Big Pharma. From 2016 to 2020, the 14 largest pharmaceutical firms spent $577 billion on buybacks and dividends—$56 billion more than they invested in R&D (PharmaVoice). Even companies whose success depends on discovery are increasingly beholden to shareholder demands rather than scientific progress.

This financialization of corporate priorities turns innovation into a luxury, not a necessity.

From Protection to Obstruction

The original purpose of patents was to encourage innovation by granting temporary monopolies in exchange for public disclosure. But today, patents are more often deployed as weapons. Strategic patenting is a well-documented barrier to competition and innovation. Drug companies often file multiple follow-on patents on different aspects of a single drug (such as new formulations, delivery methods, or minor chemical tweaks) to extend their exclusive rights beyond the original 20-year term – a practice critics call “evergreening.” Strategic “evergreening” allows companies to extend monopolies with trivial tweaks. In the U.S., the top 10 selling drugs are protected by an average of 74 patents each (Americafirstpolicy).

In tech, the situation is even more extreme. A single smartphone may be covered by over 250,000 patents ((https://insights.som.yale.edu/insights/are-patent-thickets-smothering-innovation). This “patent thicket” makes it nearly impossible for newcomers to innovate without running afoul of legal barriers. The result is a system optimized not for invention, but for exclusion.

A handful of giants (the likes of Google, Amazon, Facebook, Apple, and Microsoft in the U.S.; Alibaba and Tencent in China) command dominant positions in their respective domains. Their vast resources allow them not only to out-invest others in R&D if they choose, but also to buy out innovative startups before those can grow into serious challengers. This pattern of acquisitions can short-circuit the classic Schumpeterian process where new firms arise to challenge incumbents with disruptive innovations. In essence, if every promising new entrant ends up being purchased by an incumbent, competition is muted and the incentive for radical innovation may diminish (since entrepreneurs might focus on getting acquired rather than fully scaling a new disruptive business).

The Big Get Bigger

Market concentration is now a defining feature of the innovation economy. In the U.S., concentration increased in about 75% of industries between the late 1990s and early 2010s (rooseveltinstitute). In sectors like aerospace, agribusiness, and digital technology, a handful of firms control the lion’s share of revenue—and the innovation agenda.

These incumbents have both the financial muscle and the patent portfolios to buy or bury competitors. Rather than competing on innovation, they often compete on acquisition. The incentive to develop disruptive products is replaced by the incentive to exit profitably—if you can’t beat them, get bought by them.

The Global Innovation Gap

The consequences of this innovation bottleneck are even more severe in developing countries. Ten nations account for 80% of global R&D (WHO). Regions like Africa and much of Latin America remain largely outside the innovation economy—not for lack of talent, but for lack of access.

Strict international IP regimes (like TRIPS under the WTO) force developing nations to respect monopolies even when local needs are dire. For example, patent protections have delayed access to affordable medicines in many low-income countries. These rules often deny them the very leeway that once enabled now-wealthy nations to industrialize.

Meanwhile, innovation capital continues to flow toward deep financial markets in the Global North. As local industries in the Global South struggle to innovate under the weight of financial and legal constraints, the global innovation divide grows ever wider.

What Can Be Done?

This is not an intractable crisis. Policymakers can rebalance the system with bold reforms:

• Redirect capital: De-incentivize share buybacks and reward companies that invest a greater share of profits into R&D.

• Reform IP laws: Tighten patent criteria to prevent evergreening and implement sector-specific reforms like shorter patent terms in fast-evolving tech sectors.

• Break monopolies: Enforce antitrust rules aggressively, especially in industries prone to “killer acquisitions” like pharmaceuticals and tech.

• Support SMEs: Expand grant programmes, simplify patent procedures, and create public-private R&D consortia to empower small innovators.

• Bridge the global divide: Enable more flexible IP rules for developing countries and invest in South-South knowledge transfer and regional innovation hubs.

A Race Against Time

The world faces complex, urgent challenges: climate change, pandemics, food insecurity, digital inequality. These demand not just innovation, but a kind of innovation that is rapid, inclusive, and purposeful.

Yet the system we’ve built is wired for incrementalism and rent-seeking. If we want breakthroughs instead of buybacks, we must redesign our economic institutions to reward invention over inertia.

Innovation is too important to be left to the whims of quarterly earnings reports. It is time to rebuild an ecosystem where the next big idea isn’t throttled by the next big dividend.

Omar Chedda is based in Jamaica and writes on innovation, economic development, and the intersection of policy and equity.